The common pathological characteristic of osteoporosis and hypercalcemia is the disorder of calcium homeostasis. Currently, salmon calcitonin (sCT), a clinical regenerative medicine, is an attractive chioice to regulate calcium metabolism for alleviation of osteoporosis and hypercalcemia. Unfortunately, serum sCT is quickly cleared in vivo, leading to its short half-life. Here, we designed a versatile hydrogel, based on salmon calcitonin-oxidized calcium alginate (sCT-OCA) conjugate and hydroxypropyl chitin (HPCH). The release profile showed that sCT could be released from HPCH hydrogels loaded with sCT-OCA conjugate (sCT-OCA-HPCH) for at least 28 days with conformation stability. The cellular test demonstrated that the biocompatible sCT-OCA-HPCH, compared with sCT formulation, had capacity in up-regulating alkaline phosphatase activity (∼63% increase) and promoting calcium to deposit into extracellular matrix (∼42% increase). These results indicated that thermosensitive sCT-OCA-HPCH hydrogel herein is a versatile platform for many applications such as calcium metabolism regulation, osteoporosis treatment, and hypercalcemia therapy.

中文翻译：

---

热敏多糖水凝胶作为鲑鱼降钙素延长释放和钙调节的多功能平台

骨质疏松症和高钙血症的常见病理特征是钙稳态失调。目前，鲑鱼降钙素（sCT）是一种临床再生药物，是调节钙代谢以减轻骨质疏松和高钙血症的诱人选择。不幸的是，血清sCT在体内迅速清除，导致半衰期短。在这里，我们基于鲑鱼降钙素氧化藻酸钙（sCT-OCA）共轭物和羟丙基甲壳质（HPCH）设计了一种多功能水凝胶。释放曲线表明，sCT可以从装有sCT-OCA共轭物（sCT-OCA-HPCH）的HPCH水凝胶中释放至少28天，且具有构象稳定性。细胞测试表明，与sCT制剂相比，生物相容性sCT-OCA-HPCH 具有上调碱性磷酸酶活性（增加约63％）并促进钙沉积到细胞外基质（增加约42％）的能力。这些结果表明，本文的热敏sCT-OCA-HPCH水凝胶是用于许多应用的通用平台，例如钙代谢调节，骨质疏松症治疗和高钙血症治疗。